Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: A comparative study against standard therapy

Journal of Chemotherapy

Volumn 14, Issue 6, 2002, Pages 609-617

  Romanelli, Giuseppe ^b   Cravarezza, P ^c   Pozzi, A ^c   Franchino, L ^a   Ravizzola, G ^c   Zulli, R ^c   Donati, P ^c   Prometti, P ^c   Grassi, V ^c  

^a Astra Zeneca Medical Division   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c NONE

Author keywords

Carbapenems; Community acquired pneumonia; Elderly

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; MEROPENEM;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOSSITIS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VERTIGO;

EID: 12244258209     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.6.609     Document Type: Article

References (49)

1. Rajagopalan S, Yoshikawa T. Antimicrobial therapy in the elderly. Antibiot Ther 2001; 1:133-47.
2. Maston BJ, Plouffe JF, File Jr TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709-18.
3. Palmer CS, Zhan C, Elixhauser A, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Therapeut 2000; 22, 2: 250-64.
4. Garcia-Ordóñez MA, Garcia-Jiménez JM, Pàez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for Community-Acquired Pneumonia. Eur J Microbiol Infect Dis 2001; 20:14-19.
5. Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly. Etiology, risk, and prognostic factors. Am J Respir Crit Care Med 1996; 154:1450-55.
6. El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163, 3: 645-51.
7. Barlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811-38.
8. Niederman MS. Community-acquired pneumonia. A North American perspective. Chest 1998; 113: 179s-182s.
9. Mandell LA, Campbell GD Jr. Nosocomial pneumonia guidelines. An international perpective. Chest 1998; 113: 188-93.
10. Naber KG, Vogel F, Scholz H. The rational use of antibiotics in general practice. Recommendations of an Expert Committee of P. Ehrlich Society for Chemotherapy. MMW 1999; 140: 118-27.
11. Niederman MS, Brass JB, Campbell GD Jr., et al. Guidelines for the initial empiric therapy of community-acquired pneumonia. Proceedings of an American Thoracic Society Consensus Conference. Am Rev Resp Dis 1993; 148: 1418-26.
12. Bernstein JM. Treatment of community-acquired pneumonia - IDSA Guidelines. Chest 1999; 115: 9s-13s.
13. Woodhead M. Community-acquired pneumonia guidelines. An international comparison. A view from Europe. Chest 1998; 113: 183s-187s.
14. Fein AM. Pneumonia in the elderly: Overview of diagnostic and therapeutic approaches. Clin Infect Dis 1999; 28: 726-9.
15. The British Thoracic Society. Guidelines for management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-50.
16. Inouye SK, Pedruzzi PN, Robinson JT, et al. The importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998; 279: 1187-93.
17. Romanelli G, Cravarezza P and Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of urinary and lower respiratory tracts. J Antimicrob Chemother 1995; Suppl. A: 109-19.
18. Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother 1989; 24 (Suppl A): 9-28.
19. Bartolini A, Colao MG, Orsi A, Nicoletti P, Corti G, Paradisi F. Comparative in vitro activity of meropenem against Italian clinical isolates of Gram-negative and Gram-positive aerobic and Gram-negative anaerobic bacteria. Rev Esp Quimioter 1992; 5 (Suppl. 4), 49-53.
20. Norrby SR, Faulkner KL, Newall PA. Differentiating meropenem and imipenem/cilastatin. Infect Dis. Clin. Pract. 1997; 6: 291-301.
21. Birnbaum J, Kahan FM, Kropp H, MacDonald S. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985; 78 (Suppl. A): 3-21.
22. Moellering RC, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum betalactam antibiotucs. J Antimicrob Chemother 1989; Suppl. A: 1-71.
23. Colardyne F, Faulkner KL on behalf of the Meropenem Serious Infections Study Group. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalised patients. J Antimicrob Chemother 1996; 38: 523-37.
24. Sikka P, Jaafar WM, Bozkanat E, El-Solh AA. A comparison of severity of illness scoring systems for elderly patients with severe pneumonia. Intensive Care Med 2000; 26: 1803-10.
25. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
26. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45: 493-6.
27. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, Pennyslvania 1990.
28. Bartlett JG, Brewer NS, Ryan KJ. Laboratory diagnosis of lower respiratory tract infections. In: Washington JA (Ed.). Cumulative techniques and procedures in clinical microbiology (Cumitech7). American society for microbiology, Washington D.C. 1978: 1-18.
29. Zar JH. Biostatistical analysis. Englewood Cliff, N J: Prentice-Hall, 1996.
30. Dixon WJ, Brown MB, Engelman L, et al. BMDP statistical software manual. Berkeley, California, University of California Press, 1990.
31. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37.
32. Schafer H, Ewing S. Pneumonia in the elderly - what makes the difference? Wien Klin Wochenschr 2000; 112 (13): 566-75.
33. Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team Cohort Study. Arch Intern Med 1997; 157: 47-56.
34. Ahkee S, Srinath L, Ramirez J. Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leucocytosis. South Med J 1997; 90: 863-4.
35. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157: 1453-59.
36. Furrer M, Cottagnoud P, Mühlemann K. Haemophilus influenzae infections among hospitalized adult patients. Infection 2000; 28: 351-4.
37. Nadler HL, Sheikh W. A comparison of the in vitro postantibiotic effect of meropenem and imipenem versus selected Enterobacteriaceae and other pathogens. Diagn Microbiol Infect Dis 1993; 17: 71-3.
38. Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management and prevection. Am J Med 1998; 105: 319-30.
39. Marry TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalisation: 5-year prospective study. Rev Infect Dis 1989; 11: 586-99.
40. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; Suppl. 36 A: 1-17.
41. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 (suppl. A): 207-23.
42. Patel JB, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J. Antimicrob Chemother 1995; 24 (Suppl. A): 307-9.
43. Freifeld AG, Walsh T, Marshall T et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazime versus imipenem. J Clin Oncol 1995; 13: 165-76.
44. Mouton CP, Bazaldua OV. Common Infections in older adults. Am Fam Physician 2001; 63: 257-8.
45. Norwegian Study Group. Imipenem/cilastatin as monotherapy in severe infections: Comparison with cefotaxime in combination with metronidazole and cloxacillin. Scand J Infect Dis 1987; 19: 667-75.
46. Wang C, Calandra GB, Aziz MA, Brown KR. Efficacy and safety of imipenem/cilastatin: a review of world-wide clinical experience. Rev Infect Dis 1985; 7 (suppl3): 528s-36s.
47. McCue J. Antibiotic use in the elderly: issues and nonissues. Clin Infect Dis 1999; 28: 750-2.
48. A Guidance Document for the Costing Process, Version 1.0. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment; August 1996.
49. Ontario Medical Association. 1998 Schedule of Benefits. Toronto: Ontario Medical Association; 1998.